Otologic effects of topical mitomycin C: phase I-evaluation of ototoxicity.
OBJECTIVE
To determine ototoxicity of topical mitomycin C when placed in the middle ear at varying concentrations.


BACKGROUND
Despite meticulous surgical technique and diligent postoperative care, some patients develop excessive scar and granulation tissue in the middle ear or mastoid cavity. Poor wound healing may result in infection, tympanic membrane perforation, or conductive hearing loss, which may necessitate further surgery. Use of topical mitomycin C in the ear may be beneficial in reducing scar and granulation tissue formation. This phase of the study was developed to determine the safety of topical mitomycin C in the rat model relative to ototoxicity.


METHODS
Twelve Sprague-Dawley rats were evaluated with auditory brainstem response testing before and after treatments. Topical mitomycin C was injected in the middle ear of the right ear of eight animals. Varying concentrations of 0.125 to 0.5 mg/ml were used. Saline was injected in the left ear of each animal to serve as a control. Four separate animals were evaluated with placement of topical mitomycin C on Gelfoam into the middle ear. In two animals, Gelfoam was placed in the middle ear for 1 minute and then removed. In two animals, Gelfoam was placed in the middle ear and left in place. Auditory brainstem response testing was performed at 4 weeks and at 8 weeks.


RESULTS
Using a high concentration of mitomycin C (>0.25 mg/ml) resulted in ototoxicity, with an increase in the auditory brainstem response threshold at 4 weeks and at 8 weeks. At low concentrations (<0.20 mg/ml), no change in auditory brainstem response threshold was noted. Animals treated with Gelfoam soaked in mitomycin C showed no change in auditory brainstem response threshold.


CONCLUSIONS
The results of this study indicate that topical mitomycin C on Gelfoam applied in the middle ear appears safe when low concentrations are used, even in the rat, which has a higher susceptibility to gentamycin toxicity than humans. Higher concentrations may lead to ototoxicity based on changes in Wave V on auditory brainstem response. This treatment may prove to be an important option for patients suffering from chronic granulation tissue or scar tissue in the external or middle ear.
Babu
Seilesh C
SC
Michigan Ear Institute, Farmington Hills, Wayne State University, Detroit, Michigan, USA.
Kartush
Jack M
JM
Patni
Aftab
A
D000287:Administration, Topical; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000633:toxicity*; D001309:Auditory Threshold / Q000187:drug effects; D002921:Cicatrix / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D004432:Ear, Middle / Q000187:drug effects* / Q000473:pathology; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects*; D005781:Gelatin Sponge, Absorbable; D005839:Gentamicins / Q000633:toxicity; D006314:Hearing Loss, Conductive / Q000139:chemically induced / Q000473:pathology; D008416:Mastoid / Q000187:drug effects* / Q000473:pathology; D016685:Mitomycin / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014945:Wound Healing / Q000187:drug effects*
D000903:Antibiotics, Antineoplastic; D005839:Gentamicins; D016685:Mitomycin